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Background: Chikungunya virus (CHIKV) infection is a febrile
illness that is rarely fatal, but causes incapacitating arthralgia that
persists in convalescence. Unusual clinical presentations with high
morbidity are reported in the recent epidemics. The virus genome
is under selective pressure to adapt to arthropod and human
hosts to sustain transmission. Vaccination is the most feasible and
cost-effective option to block virus transmission during epidemics.
However, in the absence of data from deployment of CHIKV vac-
cine, and lack of reference reagents, the challenge was to qualify a
ﬁeld isolate as vaccine strain, and to deﬁne a correlate of protective
immunity for clinical development.
Methods & Materials: Phylogenetic reconstruction of CHIKV
sequences was performed in MEGA5. Selection was inferred by
Codon-based Maximum Likelihood estimates in HyPhy. Genome
sequencing and adventitious agents testing were performed by
Next Generation Sequencing (NGS). Neutralizing antibodies were
estimated by 50% Plaque Reduction Neutralization Test (PRNT50)
in CHIKV convalescent sera, vaccine antisera and in cross neutral-
ization studies. Antibody isotypes and avidity were estimated by
ELISA. GMP vaccine production was established, and pre-clinical
toxicity studies were outsourced to a GLP laboratory.
Results: The study identiﬁed a novel E1-K211E mutation under
signiﬁcant positive selection in 2009-2010 isolates which formed a
distinct clade within the ECSA (East, Central, and South African)
genotype. Vaccine antisera and CHIKV convalescent sera from
2006-2013, cross neutralized Asian and ECSA heterotypic vari-
ants from 1963 to 2010. Vaccine virus banks were certiﬁed free of
adventitious agents by sensitive NGS technology. High immuno-
genicity was established by iterative inactivation methods and
animal testing. The candidate vaccine elicited neutralizing antibod-
ies in animals comparable to the levels in convalescent subjects
(GMT, 1021 by PRNT50) (95%CI 763, 1366). Spearman-Karber esti-
mates ofmedian effective and protective doses were established in
animal challenge studies. Neutralizing IgG3 isotype and antibodies
with high avidity were elicited by the vaccine. In GLP pre-clinical
toxicity studies, the vaccine elicited no adverse and arthritogenic
effect in animals.
Conclusion: The indigenously developed Chikungunya vaccine
using a ﬁeld isolate of the virus, provides a scientiﬁc basis for devel-
oping safe, immunogenic and cost-effective vaccine for emerging
infections, and to address an unmet healthcare need in developing
countries.
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Background: The 2014 outbreak of Ebola haemorrhagic fever
(EHF) has claimed > 11,000 lives. No vaccines or antivirals are
available for EHF, but are currently the subject of intense inves-
tigations. Several vaccines targeting the Ebola virus glycoprotein
(GP) are currently under different phases of clinical testing, where
GP is delivered through chimpanzee adenovirus (Ad) 3 (Glax-
oSmithKline), vesicular stomatitis virus (Merck), human Ad26
and35 (Johnson & Johnson) or human Ad5 (Beijing Institute of
Biotechnology and Tianjin CanSino Biotechnology). Among these,
adenoviruses are well studied and are considered to be potent
inducers of cellular and humoral immunity.
Methods & Materials: A probable drawback of constitutive GP
expression as followed by all the Ad vaccine platforms mentioned
above is the potential toxicity of GP to the cell substrate, lead-
ing to production of recombinant Ad clones with low levels of GP
expression. We developed a vaccine candidate based on human
Ad5 with controlled expression of GP during the production of the
vector. The cell substrate (293 IQ cells; MicrobixBiosystems Inc.,
Canada) constitutively expresses lac-repressor which suppress the
CMV promoter driven expression of GP through a lac-operator. In
the absence of lac-repressor (e.g., in Vero E6 and 293 cells), the Ad
vectors expressed GP without any control. On addition of IPTG to
the 293 IQ cells, the inhibition of the Ad-based GP expression is
reversed.
Two clones (AdGP1 and AdGP2) and one control Ad virus were
tested in Balb/C mice for immunogenicity. The mice were divided
into 8 groups of 3 animals each. Four groups received three doses
of PBS or control Ad virus or AdGP1 or AdGP2 through intra-nasal,
followed by sub-cutaneous and intra-nasal routewhile the remain-
ing 4 groups were immunized through sub-cutaneous followed by
intra-nasal and intra-nasal route.
Results: The ELISA results indicate that AdGP1 and AdGP2
are immunogenic but there was no signiﬁcant difference in the
immunogenicity in both regimens of immunization. On the other
hand, even after three immunizations neutralizing antibody titers
to Ad virus were ≤ 1: 200.
Conclusion: Ad vector platformwith controlled protein expres-
sion can be used for other potentially toxic antigens. Further testing
and characterization of the vaccine candidate is underway.
http://dx.doi.org/10.1016/j.ijid.2016.02.896
